TransMedics Group, Inc.

Total Valuation

TransMedics Group, Inc. carries a market capitalization of 3.11B, placing it among publicly traded companies globally. Its enterprise value stands at 2.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TransMedics Group, Inc. currently has 34.63M shares outstanding.

Valuation Ratios

TransMedics Group, Inc. trades at a trailing price-to-earnings ratio of 15.03. The price-to-sales ratio is 3.41, and the price-to-book ratio stands at 4.44.

Enterprise Valuation

On an enterprise value basis, TransMedics Group, Inc. trades at an EV/EBITDA multiple of 22.83 and an EV/FCF ratio of 10.48. The EV/Sales ratio of 4.03 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.03 provides insight into valuation relative to core operating earnings.

Financial Position

TransMedics Group, Inc. maintains a current ratio of 6.62, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 167.50, indicating elevated leverage, while an interest coverage ratio of 5.56 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, TransMedics Group, Inc. has paid -79.14M in income taxes, reflecting an effective tax rate of 38.13.

Stock Price Statistics

TransMedics Group, Inc.'s stock has declined approximately -14.77553% over the past 52 weeks. The 50-day moving average sits at 80.14, while the 200-day moving average is 104.76.

Income Statement

Over the trailing twelve months, TransMedics Group, Inc. generated 668.47M in revenue and converted that into 151.70M in net income, yielding earnings per share of 3.83. EBITDA reached 118.03M, while operating income came in at 81.61M.

Balance Sheet

TransMedics Group, Inc. holds 472.68M in cash and equivalents against 867.72M in total debt, resulting in a net debt position of 41.33M. Total book value stands at 518.05M, with working capital of 552.84M providing operational flexibility.

Cash Flow

TransMedics Group, Inc. produced 145.93M in operating cash flow over the past twelve months. After subtracting -66.89M in capital expenditures, free cash flow totaled 79.04M - equivalent to 2.30 per share.

Margins

TransMedics Group, Inc. operates with a gross margin of 58.69, reflecting its pricing power and cost economics. The operating margin of 12.21 and net profit margin of 22.69 provide insight into operational efficiency.

Dividends & Yields

Scores

TransMedics Group, Inc. posts an Altman Z-Score of 2.31, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.